These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A; JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921 [TBL] [Abstract][Full Text] [Related]
26. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Boffa G; Massacesi L; Inglese M; Mariottini A; Capobianco M; Moiola L; Amato MP; Cottone S; Gualandi F; De Gobbi M; Greco R; Scimè R; Frau J; Zimatore GB; Bertolotto A; Comi G; Uccelli A; Signori A; Angelucci E; Innocenti C; Ciceri F; Repice AM; Sormani MP; Saccardi R; Mancardi G; Neurology; 2021 Feb; 96(8):e1215-e1226. PubMed ID: 33472915 [TBL] [Abstract][Full Text] [Related]
27. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868 [TBL] [Abstract][Full Text] [Related]
28. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983 [TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up more than 10 years after HSCT: a monocentric experience. Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686 [TBL] [Abstract][Full Text] [Related]
31. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Nabizadeh F; Pirahesh K; Rafiei N; Afrashteh F; Ahmadabad MA; Zabeti A; Mirmosayyeb O Neurol Ther; 2022 Dec; 11(4):1553-1569. PubMed ID: 35902484 [TBL] [Abstract][Full Text] [Related]
32. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183 [TBL] [Abstract][Full Text] [Related]
33. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis]. Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717 [TBL] [Abstract][Full Text] [Related]
34. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792 [TBL] [Abstract][Full Text] [Related]
35. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838 [TBL] [Abstract][Full Text] [Related]
36. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439 [TBL] [Abstract][Full Text] [Related]
37. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center. Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007 [TBL] [Abstract][Full Text] [Related]
38. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Bose G; Rush C; Atkins HL; Freedman MS Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969 [TBL] [Abstract][Full Text] [Related]
39. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life. Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284 [TBL] [Abstract][Full Text] [Related]
40. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]